Morgan Stanley thinks this little-known autoimmune biotech stock can surge more than 40% Kyverna began trading on the Nasdaq on Feb. 8, when it jumped 56% to reach a market cap of $1.4 billion.
In blow to Newsmax, judge rules Smartmatic's case over 2020 election lies will go to trial this month …